Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael S. Seaman, Ph.D.

Co-Author

This page shows the publications co-authored by Michael Seaman and Kathryn Stephenson.
Connection Strength

1.283
  1. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021 04 20; 325(15):1535-1544.
    View in: PubMed
    Score: 0.243
  2. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2020 09; 20(9):1061-1070.
    View in: PubMed
    Score: 0.228
  3. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). Lancet HIV. 2020 06; 7(6):e410-e421.
    View in: PubMed
    Score: 0.224
  4. Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. Open Forum Infect Dis. 2016 Apr; 3(2):ofw100.
    View in: PubMed
    Score: 0.173
  5. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 08 14; 26(2):296.
    View in: PubMed
    Score: 0.054
  6. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 01 09; 25(1):59-72.e8.
    View in: PubMed
    Score: 0.052
  7. Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys. J Virol. 2018 08 01; 92(15).
    View in: PubMed
    Score: 0.050
  8. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018 07 13; 218(4):633-644.
    View in: PubMed
    Score: 0.050
  9. Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol. 2018 07 01; 92(13).
    View in: PubMed
    Score: 0.050
  10. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018 02 10; 391(10120):563-571.
    View in: PubMed
    Score: 0.048
  11. Common features of mucosal and peripheral antibody responses elicited by candidate HIV-1 vaccines in rhesus monkeys. J Virol. 2014 Nov; 88(22):13510-5.
    View in: PubMed
    Score: 0.038
  12. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013 Nov 14; 503(7475):224-8.
    View in: PubMed
    Score: 0.036
  13. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013 Oct 24; 155(3):531-9.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.